CDNACareDx, Inc.

Ticker: CDNA | Price: $90.00 | Today's Change: +25.83%

---

What Happened

CareDx, Inc. filed an 8-K with the SEC on October 29, 2026, disclosing its financial results for the third quarter of fiscal year 2026 under Items 2.02 and 7.01. Revenue for Q3 FY2026 came in at $271.4 million, a figure that underscores a dramatic growth trajectory for the transplant diagnostics company — particularly striking when placed alongside the $11.6 million in revenues recorded back in Q1 FY2018, which also appears in the filing's XBRL data. The company reported a net loss of $10.4 million (basic and diluted EPS of -$0.32) and an operating loss of $24.7 million for the quarter.

---

Why It Matters

The market's reaction — a single-session gain of more than 25% — signals that the $271.4 million top-line print materially exceeded investor expectations heading into the print. For a company that has grown revenues by roughly 23x from Q1 FY2018 levels, the trajectory of the business is clearly the dominant narrative. While the operating loss of $24.7 million and net loss of $10.4 million confirm that CareDx has not yet reached full-year profitability, the gap between revenue scale and operating losses is narrowing in relative terms — a dynamic investors are clearly rewarding. The key near-term question is whether the company can translate its expanding top-line scale into sustained operating leverage.

---

Analysis

This is a meaningful result for CareDx. Revenue of $271.4 million in a single quarter, from a base of roughly $11.6 million just eight years prior, reflects the maturation of the transplant surveillance diagnostics market and CareDx's apparent ability to capture a growing share of it. The stock's sharp single-day move suggests the result caught the Street off-guard — this kind of gap-up move rarely happens when results merely meet consensus.

The persistence of operating losses ($24.7 million) alongside this revenue scale will be a focus for anyone assessing the path to profitability. The gap between revenue and operating income suggests continued investment in commercial infrastructure, R&D, or both. Investors will want clarity on gross margin trends and whether operating expenses are growing slower than revenue — the key indicator of emerging operating leverage.

It is also worth noting that this report follows StockWatch's existing coverage, which was initiated in September 2026. The stock has moved well above the levels contemplated at that time, reflecting the degree to which this quarterly result has reshaped near-term sentiment. Readers should consult that existing coverage for the underlying research framework, as this report's purpose is to document the event, not to re-evaluate or revise any rating or price target.

What to watch: Gross margin trends, operating expense growth rate relative to revenue, any management commentary on the path to operating profitability, and guidance for Q4 FY2026.

---

Disclaimer

This report is a news and informational summary of a publicly filed SEC disclosure. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation. No rating or price target is assigned herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decision.

Existing Coverage

StockWatch has full coverage on CDNA, published 2026-09-24. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-29. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1217234/000121723426000059/cdna-20261029.htm